A call to start hydroxyurea by 6 months of age and before the advent of sickle cell disease complications
Pediatr Blood Cancer
.
2022 Feb;69(2):e29423.
doi: 10.1002/pbc.29423.
Epub 2021 Nov 24.
Authors
Narcisse Elenga
1
,
Simon Kayemba-Kay's
2
,
Mathieu Nacher
3
,
Natasha Archer
4
Affiliations
1
Sickle Cell Disease Center, Centre Hospitalier de Cayenne, French Guiana, Cayenne, France.
2
Service de Pédiatrie, Centre Hospitalier de Chartres, Le Coudray, France.
3
INSERM U1424, Centre Hospitalier de Cayenne, French Guiana, Cayenne, France.
4
Pediatric Hematology and Oncology, Boston Children's Hospital, Boston, Massachusetts, USA.
PMID:
34818451
DOI:
10.1002/pbc.29423
No abstract available
MeSH terms
Anemia, Sickle Cell* / complications
Anemia, Sickle Cell* / drug therapy
Antisickling Agents / therapeutic use
Humans
Hydroxyurea* / adverse effects
Substances
Antisickling Agents
Hydroxyurea